Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Journal Volume
39
Journal Issue
11
Date Issued
2021-04-10
Author(s)
Dziadziuszko, Rafal
Krebs, Matthew G
De Braud, Filippo
Siena, Salvatore
Drilon, Alexander
Doebele, Robert C
Patel, Manish R
Cho, Byoung Chul
Liu, Stephen V
Ahn, Myung-Ju
Chiu, Chao-Hua
Farago, Anna F
Karapetis, Christos S
Li, Yu-Chung
Day, Bann-Mo
Chen, David
Wilson, Timothy R
Barlesi, Fabrice
Abstract
Genetic rearrangements of the tyrosine receptor kinase ROS proto-oncogene 1 (ROS1) are oncogenic drivers in non-small-cell lung cancer (NSCLC). We report the results of an updated integrated analysis of three phase I or II clinical trials (ALKA-372-001, STARTRK-1, and STARTRK-2) of the ROS1 tyrosine kinase inhibitor, entrectinib, in ROS1 fusion-positive NSCLC.
Type
journal article